Laetrile/Amygdalin Summary: Reference Numbers and the Corresponding Levels of Evidence
| Reference Number | Statistical Strength of Study Design | Strength of Endpoints Measured | Combined Score |
| [1] | 3iii Nonconsecutive case series | Diii Indirect surrogates -- tumor response rate | 3iiiDiii |
| [2] | 3iii Nonconsecutive case series | Diii Indirect surrogates -- tumor response rate | 3iiiDiii |
| [3] | 3iii Nonconsecutive case series | Diii Indirect surrogates -- tumor response rate | 3iiiDiii |
| [4] | 4 Best case series | Not applicable | 4 |
| [5] | 4 Best case series | Not applicable | 4 |
| [6] | 4 Best case series | Not applicable | 4 |
| [7] | 3iii Nonconsecutive case series | Diii Indirect surrogates -- tumor response rate | 3iiiDiii |
References
- Moertel CG, Fleming TR, Rubin J, et al.: A clinical trial of amygdalin (Laetrile) in the treatment of human cancer. N Engl J Med 306 (4): 201-6, 1982. [PUBMED Abstract]
- Kochi M, Takeuchi S, Mizutani T, et al.: Antitumor activity of benzaldehyde. Cancer Treat Rep 64 (1): 21-3, 1980. [PUBMED Abstract]
- Kochi M, Isono N, Niwayama M, et al.: Antitumor activity of a benzaldehyde derivative. Cancer Treat Rep 69 (5): 533-7, 1985. [PUBMED Abstract]
- Cancer Commission of the California Medical Association.: The treatment of cancer with "laetriles". Calif Med 78 (4): 320-26, 1953.
- Navarro MD: Five years experience with laetrile therapy in advanced cancer. Acta Unio Int Contr Cancrum 15(suppl 1): 209-21, 1959.
- Morrone JA: Chemotherapy of inoperable cancer: preliminary report of 10 cases treated with laetrile. Exp Med Surg 20: 299-308, 1962.
- Moertel CG, Ames MM, Kovach JS, et al.: A pharmacologic and toxicological study of amygdalin. JAMA 245 (6): 591-4, 1981. [PUBMED Abstract]
